Acurx Pharmaceuticals (ACXP) Competitors $0.46 -0.19 (-29.86%) Closing price 03/7/2025 04:00 PM EasternExtended Trading$0.47 +0.01 (+3.00%) As of 03/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACXP vs. ANEB, OTLK, NBRV, PDSB, IMMX, ELYM, RVPH, OKYO, KALA, and SPROShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Anebulo Pharmaceuticals (ANEB), Outlook Therapeutics (OTLK), Nabriva Therapeutics (NBRV), PDS Biotechnology (PDSB), Immix Biopharma (IMMX), Eliem Therapeutics (ELYM), Reviva Pharmaceuticals (RVPH), OKYO Pharma (OKYO), KALA BIO (KALA), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Anebulo Pharmaceuticals Outlook Therapeutics Nabriva Therapeutics PDS Biotechnology Immix Biopharma Eliem Therapeutics Reviva Pharmaceuticals OKYO Pharma KALA BIO Spero Therapeutics Acurx Pharmaceuticals (NASDAQ:ACXP) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, institutional ownership, risk and profitability. Which has preferable earnings & valuation, ACXP or ANEB? Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.58M-$1.09-0.42Anebulo PharmaceuticalsN/AN/A-$8.20M-$0.28-3.82 Is ACXP or ANEB more profitable? Anebulo Pharmaceuticals' return on equity of -119.54% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -392.36% -223.78% Anebulo Pharmaceuticals N/A -119.54%-108.08% Which has more volatility and risk, ACXP or ANEB? Acurx Pharmaceuticals has a beta of -1.71, meaning that its stock price is 271% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -1.09, meaning that its stock price is 209% less volatile than the S&P 500. Do insiders and institutionals believe in ACXP or ANEB? 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 29.6% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 85.9% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer ACXP or ANEB? Acurx Pharmaceuticals presently has a consensus price target of $12.00, indicating a potential upside of 2,524.10%. Anebulo Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 647.66%. Given Acurx Pharmaceuticals' higher probable upside, equities analysts plainly believe Acurx Pharmaceuticals is more favorable than Anebulo Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ACXP or ANEB? Acurx Pharmaceuticals received 6 more outperform votes than Anebulo Pharmaceuticals when rated by MarketBeat users. Likewise, 93.75% of users gave Acurx Pharmaceuticals an outperform vote while only 90.00% of users gave Anebulo Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAcurx PharmaceuticalsOutperform Votes1593.75% Underperform Votes16.25%Anebulo PharmaceuticalsOutperform Votes990.00% Underperform Votes110.00% Does the media prefer ACXP or ANEB? In the previous week, Acurx Pharmaceuticals had 4 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 5 mentions for Acurx Pharmaceuticals and 1 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.36 beat Acurx Pharmaceuticals' score of 0.31 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acurx Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anebulo Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAnebulo Pharmaceuticals beats Acurx Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Remove Ads Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.92M$7.31B$5.86B$8.33BDividend YieldN/A2.75%4.89%4.02%P/E Ratio-0.426.2925.1819.36Price / SalesN/A224.97378.11118.07Price / CashN/A65.6738.1234.62Price / Book1.356.517.304.23Net Income-$14.58M$140.25M$3.19B$247.13M7 Day Performance-35.55%-2.36%-1.61%-2.38%1 Month Performance-40.94%-3.90%-3.73%-6.15%1 Year Performance-84.29%-10.34%13.02%2.83% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals3.2018 of 5 stars$0.46-29.9%$12.00+2,524.1%-84.3%$8.92MN/A-0.423News CoverageHigh Trading VolumeANEBAnebulo Pharmaceuticals2.6276 of 5 stars$1.11-4.3%$8.00+620.7%-63.7%$45.60MN/A-3.964Gap DownOTLKOutlook Therapeutics1.2046 of 5 stars$1.42-5.3%$10.20+618.3%-81.1%$45.46MN/A-0.1920NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070PDSBPDS Biotechnology1.3222 of 5 stars$1.21-9.0%$11.67+864.2%-77.5%$45.27MN/A-1.0420Analyst ForecastNews CoverageGap UpIMMXImmix Biopharma2.0884 of 5 stars$1.62-9.0%$7.00+332.1%-52.9%$44.56MN/A-1.919Positive NewsELYMEliem TherapeuticsN/A$1.45+4.3%N/A-46.2%$43.14MN/A-2.749Gap DownRVPHReviva Pharmaceuticals3.8725 of 5 stars$1.28-11.1%$11.40+790.6%-67.1%$42.80MN/A-1.155Short Interest ↓News CoverageOKYOOKYO Pharma2.7465 of 5 stars$1.26+0.0%$7.00+455.6%-0.7%$42.63MN/A0.007Short Interest ↓Positive NewsKALAKALA BIO3.529 of 5 stars$6.99+0.9%$15.00+114.6%-6.0%$42.58M$3.89M-0.5630Gap DownSPROSpero Therapeutics4.23 of 5 stars$0.77-0.7%$5.00+549.3%-53.1%$41.98M$89.87M11.00150Upcoming Earnings Remove Ads Related Companies and Tools Related Companies Anebulo Pharmaceuticals Alternatives Outlook Therapeutics Alternatives Nabriva Therapeutics Alternatives PDS Biotechnology Alternatives Immix Biopharma Alternatives Eliem Therapeutics Alternatives Reviva Pharmaceuticals Alternatives OKYO Pharma Alternatives KALA BIO Alternatives Spero Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACXP) was last updated on 3/9/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
